| Company Name: | GlaxoSmithKline PLC | | Ticker Symbol: | GSK | | | WWW Address: | www.gsk.com | | CEO: | Andrew Witty | | No. of Employees: | 99,003 | | Common Issue Type: | AD | | Business Description: | A global healthcare Group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products including vaccines, over-the-counter medicines and health-related consumer products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 42.14 |  0.0 | 42.26 | 42.3 | 0 | 42.70 | 41.97 | 105922 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 119,285.7 | 2,830.7 | 0.63 | 2.53 | 2.20 | 25.6 | 4.7 | 42.70 - 27.15 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 42.14 | $ | | PE Ratio - LTM | 25.6 | |
| Market Capitalisation | 119,283.9 | mil |
| Latest Shares Outstanding | 2,830.7 | mil |
| Earnings pS (EPS) | 2.53 | $ |
| Dividend pS (DPS) | 2.20 | ¢ |
| Dividend Yield | 4.7 | % |
| Dividend Payout Ratio | 85 | % |
| Revenue per Employee | 353,647 | $ |
| Effective Tax Rate | 28.8 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 21,000 | mil |
| Domestic Sales | 14,012 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 16.60 | % |
| Gross Profit Margin | 82.3 | % |
| EBITDA Margin | 31.8 | % |
| Pre-Tax Profit Margin | 24.7 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | 6.4 | % |
| Return on Equity (ROE) | 28.4 | % |
| Return on Capital Invested (ROCI) | 10.8 | % |
| Current Ratio | 1.6 | |
| Leverage Ratio (Assets/Equity) | 4.5 | |
| Interest Cover | 9.4 | |
| Total Debt/Equity (Gearing Ratio) | 1.82 | |
| LT Debt/Total Capital | 62.0 | % |
| Working Capital pS | 3.51 | $ |
| Cash pS | 3.65 | $ |
| Book-Value pS | 5.24 | $ |
| Tangible Book-Value pS | -0.72 | $ |
| Cash Flow pS | 2.28 | $ |
| Free Cash Flow pS | -0.27 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 8.04 | |
| Price/Tangible Book Ratio | -58.50 | |
| Price/Cash Flow | 18.5 | |
| Price/Free Cash Flow | -158.8 | |
| P/E as % of Industry Group | 114.0 | % |
| P/E as % of Sector Segment | 150.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 10/28/2009 |
| Dividend Ex-Date | 11/03/2009 |
| Dividend Record Date | 11/05/2009 |
| Dividend Pay Date | 01/06/2010 |
| Dividend Amount | 490 |
| Type of Payment | Cash Payment |
| Dividend Rate | 1.96 |
| Current Dividend Yield | 4.7 |
| 5-Y Average Dividend Yield | 3.7 |
| Payout Ratio | 85.0 |
| 5-Y Average Payout Ratio | 57.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.5 | 100 | 18,046 | 23,529 |
| 4 Weeks | 42.70 | 39.82 | 41.16 | 2.4 | 96 | 17,253 | 276,045 |
| 13 Weeks | 42.70 | 38.30 | 39.14 | 7.7 | 100 | 14,560 | 873,600 |
| 26 Weeks | 42.70 | 32.68 | 33.71 | 25.0 | 104 | 14,541 | 1,803,040 |
| 52 Weeks | 42.70 | 27.15 | 34.44 | 22.4 | 99 | 19,170 | 4,754,244 |
| YTD | 42.70 | 27.15 | - | 13.1 | 92 | 19,207 | 4,340,761 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 41.74 | 41.61 | 40.50 | 37.65 | 35.63 | 0.63 | 0.66 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -5.32 | 26.8 | -14.99 |
| Income | -6.61 | 22.9 | -20.44 |
| Dividend | 5.66 | 53.6 | 6.12 |
| Capital Spending | 23.52 | NA | 8.49 |
| R&D | -2.53 | NA | -11.47 |
| Normalized Inc. | -6.38 | NA | -20.71 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 4.3 | -100.0 | -22.4 |
| Earnings % | -5.3 | -100.0 | -34.5 |
| EPS % | -0.2 | -100.0 | -31.9 |
| EPS $ | -0.01 | -0.71 | -1.19 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 18.41 |
| Current Ratio | 1.7 |
| Quick Ratio (Acid Test) | 1.2 |
| Liquidity Ratio (Cash) | 0.60 |
| Receivables Turnover | 3.5 |
| Average Collection Period | 103 |
| Working Capital/Equity | 91.4 |
| Working Capital pS | 3.68 |
| Cash-Flow pS | 3.02 |
| Free Cash-Flow pS | 0.85 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 3.32 |
| Financial Leverage Ratio (Assets/Equity) | 5.0 |
| Debt Ratio | 79.9 |
| Total Debt/Equity (Gearing Ratio) | 2.04 |
| LT Debt/Equity | 1.92 |
| LT Debt/Capital Invested | 92.6 |
| LT Debt/Total Liabilities | 48.4 |
| Interest Cover | 8.9 |
| Interest/Capital Invested | 2.87 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 14.13 |
| Tobin's Q Ratio | 2.11 |
| Current P/E Ratio - LTM | 25.60 |
| Enterprise Value (EV)/EBITDA | 13.84 |
| Enterprise Value (EV)/Free Cash Flow | 60.52 |
| Dividend Yield | 4.7 |
| Price/Tangible Book Ratio - LTM | -58.50 |
| Price/Book Ratio - LTM | 8.04 |
| Price/Cash Flow Ratio | 18.5 |
| Price/Free Cash Flow Ratio - LTM | -158.8 |
| Price/Sales Ratio | 4.82 |
| P/E Ratio (1 month ago) - LTM | 24.4 |
| P/E Ratio (26 weeks ago) - LTM | 13.4 |
| P/E Ratio (52 weeks ago) - LTM | 10.0 |
| 5-Y High P/E Ratio | 21.6 |
| 5-Y Low P/E Ratio | 12.3 |
| 5-Y Average P/E Ratio | 15.2 |
| Current P/E Ratio as % of 5-Y Average P/E | 169 |
| P/E as % of Industry Group | 114.0 |
| P/E as % of Sector Segment | 150.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 25.6 |
| PER SHARE FIGURES |
| LT Debt pS | 7.74 |
| Current Liabilities pS | 5.09 |
| Tangible Book Value pS - LTM | -0.72 |
| Book Value pS - LTM | 5.24 |
| Capital Invested pS | 11.76 |
| Cash pS - LTM | 3.65 |
| Cash Flow pS - LTM | 2.28 |
| Free Cash Flow pS - LTM | -0.27 |
| Earnings pS (EPS) | 2.53 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 6.87 |
| Free Cash Flow Margin 5YEAR AVG | 3.95 |
| Net Profit Margin | 19.3 |
| Net Profit Margin - 5YEAR AVRG. | 21.8 |
| Equity Productivity | 3.07 |
| Return on Equity (ROE) | 59.4 |
| Return on Equity (ROE) - 5YEAR AVRG. | 60.4 |
| Capital Invested Productivity | 1.05 |
| Return on Capital Invested (ROCI) | 20.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 32.5 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 12.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 17.0 |
| Gross Profit Margin | 82.3 |
| Gross Profit Margin - 5YEAR AVRG. | 81.7 |
| EBITDA Margin - LTM | 31.8 |
| EBIT Margin - LTM | 27.6 |
| Pre-Tax Profit Margin | 27.8 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 31.3 |
| Effective Tax Rate | 28.8 |
| Effective Tax Rate - 5YEAR AVRG. | 28.8 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 382 |
| Revenue per Employee | 353,647 |
| Net Income per Employee | 68,429 |
| Average Collection Period | 94 |
| Receivables Turnover | 3.5 |
| Day's Inventory Turnover Ratio | 288 |
| Inventory Turnover | 1.3 |
| Inventory/Sales | 16.7 |
| Accounts Payble/Sales | 24.95 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 3.36 |
| Fixed Assets Turnover | 1.10 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 4.33 |
| Revenue per $ Plant | 2.52 |
| Revenue per $ Common Equity | 3.07 |
| Revenue per $ Capital Invested | 1.05 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.1 |
| Research & Devlopment (R&D) as % of Revenue | 15.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 15.1 |
|
|  
| | |  |  | |
| |